Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market to Grow at a CAGR of 8.3% During 2024-2032, Aided by Intensive Efforts Across Market and Academia to Develop Novel Treatment Options

The clinical presentation of FSGS includes symptoms consistent with nephrotic syndrome such as peripheral oedema, significant proteinuria that may be at nephrotic levels, hypertension, hypoalbuminemia, hyperlipidemia, and deteriorating renal function over time. FSGS can occur primarily or develop secondarily due to other conditions.

The focal segmental glomerulosclerosis (FSGS) treatment market growth is being driven by the rising production of pharmaceutical products and increased research and development efforts focused on biopharmaceuticals to improve treatment efficacy. Growth in generic drug production is also anticipated to contribute to market expansion. Additionally, advancements in developing treatments for rare diseases represent important potential opportunities for the market growth during the forecast period.

The ageing population, rising incidence of risk factors like diabetes and hypertension, and availability of advanced diagnostic and treatment options are further contributing to the market expansion. In February 2023, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the United States Food and Drug Administration (FDA) has granted accelerated approval to FILSPARITM (sparsentan) for reducing proteinuria in adults with primary IgA nephropathy at high risk of rapidly progressing disease, generally indicated by a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 grams per gram.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Disease Type, Diagnosis Method, Treatment Method, Treatment Channel, and Region:

• On the basis of the disease type, the market is bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.

• The market is segmented based on diagnosis methods into kidney function testing, kidney imaging, and kidney biopsy.

• On the basis of the treatment method, the market is divided into medication, dialysis, and kidney transplant.

• The market is segmented based on treatment channel into public and private.

• By region, the market can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The increasing prevalence of focal segmental glomerulosclerosis (FSGS) and a strong emphasis on discovering novel therapeutic options are anticipated to substantially contribute to the focal segmental glomerulosclerosis (FSGS) treatment market expansion over the coming years.

• Several rising risk factors are driving the market. These include increasing rates of kidney infections, greater exposure to toxins, more genetic mutations, and a growing prevalence of underlying conditions such as HIV and sickle cell disease.

• The widespread use of certain medications that damage renal podocytes, including bisphosphonates, anabolic steroids, anthracyclines, and calcineurin inhibitors, is also driving the market growth. Furthermore, the increasing utilisation of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, represents another factor propelling the market.

• In addition, the growing use of plasmapheresis to decrease proteinuria and enhance kidney function in patients is further generating a favourable outlook for the market.

Key Offerings of the Report:

• The EMR report gives an overview of the global focal segmental glomerulosclerosis (FSGS) treatment market for the periods (2017-2023) and (2024-2032).

• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the disease types, diagnosis methods, treatment methods, treatment channels, and major regions of focal segmental glomerulosclerosis (FSGS) treatment.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, industry events, initiatives, and trends, value chain analysis, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global focal segmental glomerulosclerosis (FSGS) treatment market are Beckman Coulter Inc. (Danaher Corporation), Complexa Inc., Variant Pharmaceuticals, Inc., Travere Therapeutics, Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Aurinia Pharmaceuticals Inc., Medtronic Plc., B. Braun Melsungen AG, Bristol-Myers Squibb Co, Reata Pharmaceuticals Inc, Kyowa Hakko Kirin Co., Ltd., and Astellas Pharma Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.